StemCell Therapy

LOS ANGELES, United States: QY Research has recently published a report, titled Global and China Genomic Biomarker Market Size, Status and Forecast 2020-2026. The research report gives the potential headway openings that prevails in the global market. The report is amalgamated depending on research procured from primary and secondary information. The global and China Genomic Biomarker market is relied upon to develop generously and succeed in volume and value during the predicted time period. Moreover, the report gives nitty gritty data on different manufacturers, region, and products which are important to totally understanding the market.

Key Companies/Manufacturers operating in the global and China Genomic Biomarker market include: , Bio-Rad, Beckman Coulter, Myriad Genetics, Thermo Fisher Scientific, Roche, QIAGEN, Epigenomics, Almac, Pfizer, Human Longevity, ValiRx, Personalis, Eagle Genomics, Empire Genomics, Agilent, Illumina

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1955234/global-and-china-genomic-biomarker-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global and China Genomic Biomarker market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global and China Genomic Biomarker Market Segment By Type:

Protein MarkerNucleic Acid MarkerOther Genomic Biomarker

Global and China Genomic Biomarker Market Segment By Application:

HospitalsDiagnostic and research laboratories Based on

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global and China Genomic Biomarker market.

Key companies operating in the global and China Genomic Biomarker market include , Bio-Rad, Beckman Coulter, Myriad Genetics, Thermo Fisher Scientific, Roche, QIAGEN, Epigenomics, Almac, Pfizer, Human Longevity, ValiRx, Personalis, Eagle Genomics, Empire Genomics, Agilent, Illumina

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1955234/global-and-china-genomic-biomarker-market

TOC

1 Report Overview1.1 Study Scope1.2 Market Analysis by Type1.2.1 Global Genomic Biomarker Market Size Growth Rate by Type: 2020 VS 20261.2.2 Protein Marker1.2.3 Nucleic Acid Marker1.2.4 Other1.3 Market by Application1.3.1 Global Genomic Biomarker Market Share by Application: 2020 VS 20261.3.2 Hospitals1.3.3 Diagnostic and research laboratories 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends2.1 Global Genomic Biomarker Market Perspective (2015-2026)2.2 Global Genomic Biomarker Growth Trends by Regions2.2.1 Genomic Biomarker Market Size by Regions: 2015 VS 2020 VS 20262.2.2 Genomic Biomarker Historic Market Share by Regions (2015-2020)2.2.3 Genomic Biomarker Forecasted Market Size by Regions (2021-2026) 2.3 Industry Trends and Growth Strategy 2.3.1 Market Trends 2.3.2 Market Drivers2.3.3 Market Challenges2.3.4 Market Restraints 3 Competition Landscape by Key Players3.1 Global Top Genomic Biomarker Players by Market Size3.1.1 Global Top Genomic Biomarker Players by Revenue (2015-2020)3.1.2 Global Genomic Biomarker Revenue Market Share by Players (2015-2020)3.2 Global Genomic Biomarker Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.3 Players Covered: Ranking by Genomic Biomarker Revenue3.4 Global Genomic Biomarker Market Concentration Ratio3.4.1 Global Genomic Biomarker Market Concentration Ratio (CR5 and HHI)3.4.2 Global Top 10 and Top 5 Companies by Genomic Biomarker Revenue in 20193.5 Key Players Genomic Biomarker Area Served3.6 Key Players Genomic Biomarker Product Solution and Service3.7 Date of Enter into Genomic Biomarker Market3.8 Mergers & Acquisitions, Expansion Plans 4 Genomic Biomarker Breakdown Data by Type (2015-2026)4.1 Global Genomic Biomarker Historic Market Size by Type (2015-2020)4.2 Global Genomic Biomarker Forecasted Market Size by Type (2021-2026) 5 Genomic Biomarker Breakdown Data by Application (2015-2026)5.1 Global Genomic Biomarker Historic Market Size by Application (2015-2020)5.2 Global Genomic Biomarker Forecasted Market Size by Application (2021-2026) 6 North America6.1 North America Genomic Biomarker Market Size (2015-2026)6.2 North America Genomic Biomarker Market Size by Type (2015-2020)6.3 North America Genomic Biomarker Market Size by Application (2015-2020)6.4 North America Genomic Biomarker Market Size by Country (2015-2020)6.4.1 United States6.4.2 Canada 7 Europe7.1 Europe Genomic Biomarker Market Size (2015-2026)7.2 Europe Genomic Biomarker Market Size by Type (2015-2020)7.3 Europe Genomic Biomarker Market Size by Application (2015-2020)7.4 Europe Genomic Biomarker Market Size by Country (2015-2020)7.4.1 Germany7.4.2 France7.4.3 U.K.7.4.4 Italy7.4.5 Russia7.4.6 Nordic7.4.7 Rest of Europe 8 China8.1 China Genomic Biomarker Market Size (2015-2026)8.2 China Genomic Biomarker Market Size by Type (2015-2020)8.3 China Genomic Biomarker Market Size by Application (2015-2020)8.4 China Genomic Biomarker Market Size by Region (2015-2020)8.4.1 China8.4.2 Japan8.4.3 South Korea8.4.4 Southeast Asia8.4.5 India8.4.6 Australia8.4.7 Rest of Asia-Pacific 9 Japan9.1 Japan Genomic Biomarker Market Size (2015-2026)9.2 Japan Genomic Biomarker Market Size by Type (2015-2020)9.3 Japan Genomic Biomarker Market Size by Application (2015-2020)9.4 Japan Genomic Biomarker Market Size by Country (2015-2020)9.4.1 Mexico9.4.2 Brazil 10 Southeast Asia10.1 Southeast Asia Genomic Biomarker Market Size (2015-2026)10.2 Southeast Asia Genomic Biomarker Market Size by Type (2015-2020)10.3 Southeast Asia Genomic Biomarker Market Size by Application (2015-2020)10.4 Southeast Asia Genomic Biomarker Market Size by Country (2015-2020)10.4.1 Turkey10.4.2 Saudi Arabia10.4.3 UAE10.4.4 Rest of Middle East & Africa 11Key Players Profiles11.1 Bio-Rad11.1.1 Bio-Rad Company Details11.1.2 Bio-Rad Business Overview11.1.3 Bio-Rad Genomic Biomarker Introduction11.1.4 Bio-Rad Revenue in Genomic Biomarker Business (2015-2020))11.1.5 Bio-Rad Recent Development11.2 Beckman Coulter11.2.1 Beckman Coulter Company Details11.2.2 Beckman Coulter Business Overview11.2.3 Beckman Coulter Genomic Biomarker Introduction11.2.4 Beckman Coulter Revenue in Genomic Biomarker Business (2015-2020)11.2.5 Beckman Coulter Recent Development11.3 Myriad Genetics11.3.1 Myriad Genetics Company Details11.3.2 Myriad Genetics Business Overview11.3.3 Myriad Genetics Genomic Biomarker Introduction11.3.4 Myriad Genetics Revenue in Genomic Biomarker Business (2015-2020)11.3.5 Myriad Genetics Recent Development11.4 Thermo Fisher Scientific11.4.1 Thermo Fisher Scientific Company Details11.4.2 Thermo Fisher Scientific Business Overview11.4.3 Thermo Fisher Scientific Genomic Biomarker Introduction11.4.4 Thermo Fisher Scientific Revenue in Genomic Biomarker Business (2015-2020)11.4.5 Thermo Fisher Scientific Recent Development11.5 Roche11.5.1 Roche Company Details11.5.2 Roche Business Overview11.5.3 Roche Genomic Biomarker Introduction11.5.4 Roche Revenue in Genomic Biomarker Business (2015-2020)11.5.5 Roche Recent Development11.6 QIAGEN11.6.1 QIAGEN Company Details11.6.2 QIAGEN Business Overview11.6.3 QIAGEN Genomic Biomarker Introduction11.6.4 QIAGEN Revenue in Genomic Biomarker Business (2015-2020)11.6.5 QIAGEN Recent Development11.7 Epigenomics11.7.1 Epigenomics Company Details11.7.2 Epigenomics Business Overview11.7.3 Epigenomics Genomic Biomarker Introduction11.7.4 Epigenomics Revenue in Genomic Biomarker Business (2015-2020)11.7.5 Epigenomics Recent Development11.8 Almac11.8.1 Almac Company Details11.8.2 Almac Business Overview11.8.3 Almac Genomic Biomarker Introduction11.8.4 Almac Revenue in Genomic Biomarker Business (2015-2020)11.8.5 Almac Recent Development11.9 Pfizer11.9.1 Pfizer Company Details11.9.2 Pfizer Business Overview11.9.3 Pfizer Genomic Biomarker Introduction11.9.4 Pfizer Revenue in Genomic Biomarker Business (2015-2020)11.9.5 Pfizer Recent Development11.10 Human Longevity11.10.1 Human Longevity Company Details11.10.2 Human Longevity Business Overview11.10.3 Human Longevity Genomic Biomarker Introduction11.10.4 Human Longevity Revenue in Genomic Biomarker Business (2015-2020)11.10.5 Human Longevity Recent Development11.11 ValiRx10.11.1 ValiRx Company Details10.11.2 ValiRx Business Overview10.11.3 ValiRx Genomic Biomarker Introduction10.11.4 ValiRx Revenue in Genomic Biomarker Business (2015-2020)10.11.5 ValiRx Recent Development11.12 Personalis10.12.1 Personalis Company Details10.12.2 Personalis Business Overview10.12.3 Personalis Genomic Biomarker Introduction10.12.4 Personalis Revenue in Genomic Biomarker Business (2015-2020)10.12.5 Personalis Recent Development11.13 Eagle Genomics10.13.1 Eagle Genomics Company Details10.13.2 Eagle Genomics Business Overview10.13.3 Eagle Genomics Genomic Biomarker Introduction10.13.4 Eagle Genomics Revenue in Genomic Biomarker Business (2015-2020)10.13.5 Eagle Genomics Recent Development11.14 Empire Genomics10.14.1 Empire Genomics Company Details10.14.2 Empire Genomics Business Overview10.14.3 Empire Genomics Genomic Biomarker Introduction10.14.4 Empire Genomics Revenue in Genomic Biomarker Business (2015-2020)10.14.5 Empire Genomics Recent Development11.15 Agilent10.15.1 Agilent Company Details10.15.2 Agilent Business Overview10.15.3 Agilent Genomic Biomarker Introduction10.15.4 Agilent Revenue in Genomic Biomarker Business (2015-2020)10.15.5 Agilent Recent Development11.16 Illumina10.16.1 Illumina Company Details10.16.2 Illumina Business Overview10.16.3 Illumina Genomic Biomarker Introduction10.16.4 Illumina Revenue in Genomic Biomarker Business (2015-2020)10.16.5 Illumina Recent Development 12Analysts Viewpoints/Conclusions 13Appendix13.1 Research Methodology13.1.1 Methodology/Research Approach13.1.2 Data Source13.2 Disclaimer13.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Read the rest here:
New Report: and China Genomic Biomarker Market Share, Growth, Trend Analysis and Forecast from 2020-2026; Consumption Capacity by Volume and...

LOS ANGELES, United States: QY Research has recently published a report, titled Global Genomic Biomarker Market Report, History and Forecast 2015-2026, Breakdown Data by Companies, Key Regions, Types and Application. The research report gives the potential headway openings that prevails in the global market. The report is amalgamated depending on research procured from primary and secondary information. The global Genomic Biomarker market is relied upon to develop generously and succeed in volume and value during the predicted time period. Moreover, the report gives nitty gritty data on different manufacturers, region, and products which are important to totally understanding the market.

Key Companies/Manufacturers operating in the global Genomic Biomarker market include: Bio-Rad, Beckman Coulter, Myriad Genetics, Thermo Fisher Scientific, Roche, QIAGEN, Epigenomics, Almac, Pfizer, Human Longevity, ValiRx, Personalis, Eagle Genomics, Empire Genomics, Agilent, Illumina

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1605804/global-genomic-biomarker-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Genomic Biomarker market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Genomic Biomarker Market Segment By Type:

Protein MarkerNucleic Acid MarkerOther

Global Genomic Biomarker Market Segment By Application:

HospitalsDiagnostic and research laboratories Global Genomic Biomarker

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Genomic Biomarker market.

Key companies operating in the global Genomic Biomarker market include Bio-Rad, Beckman Coulter, Myriad Genetics, Thermo Fisher Scientific, Roche, QIAGEN, Epigenomics, Almac, Pfizer, Human Longevity, ValiRx, Personalis, Eagle Genomics, Empire Genomics, Agilent, Illumina

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1605804/global-genomic-biomarker-market

TOC

1 Market Overview of Genomic Biomarker1.1 Genomic Biomarker Market Overview1.1.1 Genomic Biomarker Product Scope1.1.2 Market Status and Outlook1.2 Global Genomic Biomarker Market Size Overview by Region 2015 VS 2020 VS 20261.3 Global Genomic Biomarker Market Size by Region (2015-2026)1.4 Global Genomic Biomarker Historic Market Size by Region (2015-2020)1.5 Global Genomic Biomarker Market Size Forecast by Region (2021-2026)1.6 Key Regions, Genomic Biomarker Market Size YoY Growth (2015-2026)1.6.1 North America Genomic Biomarker Market Size YoY Growth (2015-2026)1.6.2 Europe Genomic Biomarker Market Size YoY Growth (2015-2026)1.6.3 Asia-Pacific Genomic Biomarker Market Size YoY Growth (2015-2026)1.6.4 Latin America Genomic Biomarker Market Size YoY Growth (2015-2026)1.6.5 Middle East & Africa Genomic Biomarker Market Size YoY Growth (2015-2026) 2 Genomic Biomarker Market Overview by Type2.1 Global Genomic Biomarker Market Size by Type: 2015 VS 2020 VS 20262.2 Global Genomic Biomarker Historic Market Size by Type (2015-2020)2.3 Global Genomic Biomarker Forecasted Market Size by Type (2021-2026)2.4 Protein Marker2.5 Nucleic Acid Marker2.6 Other 3 Genomic Biomarker Market Overview by Application3.1 Global Genomic Biomarker Market Size by Application: 2015 VS 2020 VS 20263.2 Global Genomic Biomarker Historic Market Size by Application (2015-2020)3.3 Global Genomic Biomarker Forecasted Market Size by Application (2021-2026)3.4 Hospitals3.5 Diagnostic and research laboratories 4 Global Genomic Biomarker Competition Analysis by Players4.1 Global Genomic Biomarker Market Size (Million US$) by Players (2015-2020)4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Genomic Biomarker as of 2019)4.3 Date of Key Manufacturers Enter into Genomic Biomarker Market4.4 Global Top Players Genomic Biomarker Headquarters and Area Served4.5 Key Players Genomic Biomarker Product Solution and Service4.6 Competitive Status4.6.1 Genomic Biomarker Market Concentration Rate4.6.2 Mergers & Acquisitions, Expansion Plans 5 Company (Top Players) Profiles and Key Data5.1 Bio-Rad5.1.1 Bio-Rad Profile5.1.2 Bio-Rad Main Business5.1.3 Bio-Rad Products, Services and Solutions5.1.4 Bio-Rad Revenue (US$ Million) & (2015-2020)5.1.5 Bio-Rad Recent Developments5.2 Beckman Coulter5.2.1 Beckman Coulter Profile5.2.2 Beckman Coulter Main Business and Companys Total Revenue5.2.3 Beckman Coulter Products, Services and Solutions5.2.4 Beckman Coulter Revenue (US$ Million) (2015-2020)5.2.5 Beckman Coulter Recent Development and Reaction to Covid-195.3 Myriad Genetics5.5.1 Myriad Genetics Profile5.3.2 Myriad Genetics Main Business5.3.3 Myriad Genetics Products, Services and Solutions5.3.4 Myriad Genetics Revenue (US$ Million) & (2015-2020)5.3.5 Thermo Fisher Scientific Recent Developments5.4 Thermo Fisher Scientific5.4.1 Thermo Fisher Scientific Profile5.4.2 Thermo Fisher Scientific Main Business5.4.3 Thermo Fisher Scientific Products, Services and Solutions5.4.4 Thermo Fisher Scientific Revenue (US$ Million) & (2015-2020)5.4.5 Thermo Fisher Scientific Recent Developments5.5 Roche5.5.1 Roche Profile5.5.2 Roche Main Business5.5.3 Roche Products, Services and Solutions5.5.4 Roche Revenue (US$ Million) & (2015-2020)5.5.5 Roche Recent Developments5.6 QIAGEN5.6.1 QIAGEN Profile5.6.2 QIAGEN Main Business5.6.3 QIAGEN Products, Services and Solutions5.6.4 QIAGEN Revenue (US$ Million) & (2015-2020)5.6.5 QIAGEN Recent Developments5.7 Epigenomics5.7.1 Epigenomics Profile5.7.2 Epigenomics Main Business and Companys Total Revenue5.7.3 Epigenomics Products, Services and Solutions5.7.4 Epigenomics Revenue (US$ Million) (2015-2020)5.7.5 Epigenomics Recent Development and Reaction to Covid-195.8 Almac5.8.1 Almac Profile5.8.2 Almac Main Business5.8.3 Almac Products, Services and Solutions5.8.4 Almac Revenue (US$ Million) & (2015-2020)5.8.5 Almac Recent Developments5.9 Pfizer5.9.1 Pfizer Profile5.9.2 Pfizer Main Business5.9.3 Pfizer Products, Services and Solutions5.9.4 Pfizer Revenue (US$ Million) & (2015-2020)5.9.5 Pfizer Recent Developments5.10 Human Longevity5.10.1 Human Longevity Profile5.10.2 Human Longevity Main Business5.10.3 Human Longevity Products, Services and Solutions5.10.4 Human Longevity Revenue (US$ Million) & (2015-2020)5.10.5 Human Longevity Recent Developments5.11 ValiRx5.11.1 ValiRx Profile5.11.2 ValiRx Main Business5.11.3 ValiRx Products, Services and Solutions5.11.4 ValiRx Revenue (US$ Million) & (2015-2020)5.11.5 ValiRx Recent Developments5.12 Personalis5.12.1 Personalis Profile5.12.2 Personalis Main Business5.12.3 Personalis Products, Services and Solutions5.12.4 Personalis Revenue (US$ Million) & (2015-2020)5.12.5 Personalis Recent Developments5.13 Eagle Genomics5.13.1 Eagle Genomics Profile5.13.2 Eagle Genomics Main Business5.13.3 Eagle Genomics Products, Services and Solutions5.13.4 Eagle Genomics Revenue (US$ Million) & (2015-2020)5.13.5 Eagle Genomics Recent Developments5.14 Empire Genomics5.14.1 Empire Genomics Profile5.14.2 Empire Genomics Main Business5.14.3 Empire Genomics Products, Services and Solutions5.14.4 Empire Genomics Revenue (US$ Million) & (2015-2020)5.14.5 Empire Genomics Recent Developments5.15 Agilent5.15.1 Agilent Profile5.15.2 Agilent Main Business5.15.3 Agilent Products, Services and Solutions5.15.4 Agilent Revenue (US$ Million) & (2015-2020)5.15.5 Agilent Recent Developments5.16 Illumina5.16.1 Illumina Profile5.16.2 Illumina Main Business and Companys Total Revenue5.16.3 Illumina Products, Services and Solutions5.16.4 Illumina Revenue (US$ Million) (2015-2020)5.16.5 Illumina Recent Development and Reaction to Covid-19 6 North America6.1 North America Genomic Biomarker Market Size by Country6.2 United States6.3 Canada 7 Europe7.1 Europe Genomic Biomarker Market Size by Country7.2 Germany7.3 France7.4 U.K.7.5 Italy7.6 Russia7.7 Nordic7.8 Rest of Europe 8 Asia-Pacific8.1 Asia-Pacific Genomic Biomarker Market Size by Region8.2 China8.3 Japan8.4 South Korea8.5 Southeast Asia8.6 India8.7 Australia8.8 Rest of Asia-Pacific 9 Latin America9.1 Latin America Genomic Biomarker Market Size by Country9.2 Mexico9.3 Brazil9.4 Rest of Latin America 10 Middle East & Africa10.1 Middle East & Africa Genomic Biomarker Market Size by Country10.2 Turkey10.3 Saudi Arabia10.4 UAE10.5 Rest of Middle East & Africa 11 Genomic Biomarker Market Dynamics11.1 Industry Trends11.2 Market Drivers11.3 Market Challenges11.4 Market Restraints 12 Research Finding /Conclusion 13 Methodology and Data Source 13.1 Methodology/Research Approach13.1.1 Research Programs/Design13.1.2 Market Size Estimation13.1.3 Market Breakdown and Data Triangulation13.2 Data Source13.2.1 Secondary Sources13.2.2 Primary Sources13.3 Disclaimer13.4 Author List

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Read more here:
New Report: Genomic Biomarker Market: Reporting and Evaluation of Recent Industry Developments| Bio-Rad, Beckman Coulter, Myriad Genetics, Thermo...

Long life spans tend to run in families, a phenomenon that's often attributed to people's genes. But now, a large new study of data from the genealogy website Ancestry reveals that genetics may play less of a role in life span than previously thought.

The reason? Previous studies failed to take into account a quirk of human relationships: that people tend select romantic partners with similar traits to their own. The findings mean that previous studies may have substantially overestimated the heritability of life span, the researchers said.

The study was published in today (Nov. 6) in the journal Genetics. It was funded by Calico Life Sciences, a research and development company owned by Alphabet Inc. (Google's parent company) whose mission is to understand the biology of aging. [7 Ways the Mind and Body Change With Age]

In a given population, people will vary in a number of ways; they'll have different heights, eye colors and, yes, life spans.

Heritability is a measure of how much of the variability in a given trait, such as life span, is explained by variability in people's genes, in contrast to environmental factors such as healthy eating or exercise. Previous studies have estimated that the heritability of life span is as high as 30 percent.

In the new study, the researchers analyzed information from more than 400 million people using publicly available family trees from Ancestry. Because the researchers needed to know the life span of these individuals, the study looked at only those who were born in the 1800s or early 1900s and were deceased. (Before sharing this data, Ancestry removed all identifiable information from the family trees.)

An initial analysis revealed that, when comparing the life spans of siblings and first cousins, the heritability of life span appears to be around 20 to 30 percent similar to what's been found previous studies.

But the life spans of spouses also tended to be similar. This could be due to spouses sharing a similar environment, the study said. Because they live in the same household, they may share many nongenetic factors, from diet to sleep habits, that could influence life span.

But then the researchers noted something curious: They found that even siblings-in-law and first-cousins-in-law had correlated lifespans, despite not generally living in the same household or being blood relatives.

But if they didn't share a close family history or a similar environment, why did remote and non-blood relatives also have linked life spans? The large data set allowed researchers to examine the effect of what's called assortative mating, the phenomenon in which people tend to select spouses who are similar to themselves. If assortative mating was at play, it would mean that factors that are important for life span tend to be similar among spouses, Graham Ruby, lead author of the study and a principal investigator at Calico Life Sciences, said in a statement.

Indeed, the researchers found that this was the case, and when they accounted for assortative mating, the heritability of life span dropped to 7 percent.

However, the study is not saying that people select a mate based on their life span, as that would be impossible, Ruby said. "Generally, people get married before either one of them has died," Ruby said jokingly.

But other factors could be at play, including both genetic and nongenetic variables. For example, if wealth is tied to life span and wealthy people tend to marry other wealthy people, this could make life span appear to be more heritable than it really is, the researchers said. Or if height a trait that is partly influenced by genetics is linked to life span and tall people tend to marry other tall people, then this would also muddle the analysis of the heritability of life span.

However, the findings don't mean that there aren't genes for longevity. The study focused on the heritability of life span on a population level and did not look specifically at people's genomes. Previous studies have found a link between certain genes and a long life.

Originally published on Live Science.

Read more:
A Longer Life May Not Be in Your Genes | Live Science

Significant reproductive and performance benefits have been achieved in dairy cows by adding a yeast probiotic to their feed rations, according to the results from a major French trial in which the probiotic boosted conception rates and milk yields.

Dairy farmers are constantly seeking to improve cow health and welfare, reproduction rates and milk yields. Advancing cow longevity and the number of productive lactations is also important to producers as they cope with ever-tightening margins.

In addition to helping spread heifer replacement costs over a maximum number of productive years, multi-lactation cows are also more likely to reach their genetic potential than those which only calve once or twice. The highest average milk yields, for example, are routinely achieved after the 3rd lactation.

Supplementing dairy cow diets with the yeast probiotic not only improves milk production and milk solids but also boosts dairy cow fertility and may contribute to greater longevity. Photo: Shutterstock

The increasing use of beef genetics on dairy farms is another rising trend, designed to boost the meat value of calves born to cows which arent required to breed dairy replacements. This is only possible, however, when farmers are sure of getting strong reproduction from their best milking cows, with reproductive failure identified as the main reason otherwise valuable cows are culled early.

Good reproduction in high-yielding dairy cows results in greater lifetime milk output, more calves, lower replacement costs and lower relative breeding costs. A Dutch dairy study reported that raising reproductive performance can increase net profits by 34 to 231 per cow.

Fertility is affected by several factors, including genetics, nutrition, welfare, stress at calving, heat stress, negative energy balance and so on. This is the context, therefore, in which adding probiotics to diets could help improve overall cow health and may have a positive effect on reproductive performance.

Trial results show that supplementing dairy cows during transition with the yeast probiotic Actisaf Sc 47, significantly reduces inflammatory markers around calving and BHBA blood levels. It also appears to increase feed intake before and after calving. Given that negative energy balance and systemic inflammation around calving can seriously affect future fertility rates, its estimated that supplementing diets with yeast probiotics may help improve reproductive performance.

To further assess the reproductive impact on dairy cows of supplementing diets with a yeast probiotic, the animal genetics and reproduction technologies group, Gnes Diffusion, and the animal care company, Phileo by Lesaffre, carried out a large-scale study involving approximately 2,500 dairy cows. Spread across 14 French farms and conducted over 3 years, the study involved probiotic supplementation being given to lactating cows, mixed into their daily ration, at a rate of 5g per cow.

Study results revealed statistical differences in production and reproduction, with supplemented multiparous cows achieving significantly higher artificial insemination success rate at first insemination (36% vs 31%) (Figure 1) and significantly lower number of inseminations per pregnancy (2.7 vs 3.1) than cows in a non-supplemented reference period covering the previous 2 years (Figure 2).

There was also an increase in milk fat and protein yields (2,246 vs 2,360g/d) in supplemented cows and an extra 1.5 litres per cow per day of increased milk production.

The study concluded that supplementing dairy cow diets with the yeast probiotic not only improves milk production and milk solids but also boosts dairy cow fertility and may contribute to greater longevity. As for the cost benefits of supplementation, the calculated return on investment (ROI) from using the probiotic during the study period, was 6:1.

Authors: Mohamed Mammeri, PhD, Global Product Manager, Phileo by Lesaffre & Valentin Nenov, PhD, Global Ruminant Manager, Phileo by Lesaffre.

References are available from the author on request

Here is the original post:
Improving dairy cow reproduction through nutrition - All about feed

In the era of technologies and digital screens, millions of products are marketed as healthy. But why is it a growing number of individuals are challenged with chronic diseases and mental illnesses? Here is maintaining perfect health in the world of new technologies and devices.

- Advertisement -

While we have nutrition and fitness apps at our fingertips, the harsh reality is why these live-saving apps and tech are nowhere near as popular as fast food delivery apps. Internet addiction and trolls may also put some vulnerable people at risk of mental illnesses.

To live a healthy happy life in the midst of convenient choices, we must embrace the power of technology while practicing the most primitive ways of achieving health.

- Advertisement -

Unleash the power of your genetics

Recently, CRISPR-based therapy was used to treat inherited blindness for the new in history. This officially brings human gene-editing from science fiction to reality.

Your DNA is the blueprint for building you your eye color, ancestry, and risks of genetic diseases.

If your quality of life is partly determined by genetics, doesnt it make sense to crack this code and prepare for what the future holds?

Indeed, commercial genetic testing has gained rapid popularity all over the world. Dozens of organizations like 23anMe are competing to offer you the most comprehensive genetic interpretations.

In our genetic makeup, millions of single-nucleotide polymorphisms, or SNPs, hold the secrets to your:

With this information, you are able to take active actions to enhance your lifestyle, inform your doctor, and manage potential diseases. Our medical system is moving towards a thrilling era of personalized data-driven practice these days.

Did you know our gut has 10 times the amount of cells compared to anything else in the body combined?

Its huge. Our gut houses at least 1000 different types of bacteria the good, the bad, and the ugly.

For good bacteria to flourish in our gut, we need to feed them with fermentable fibre from plant-based foods, also called prebiotics. With these healthier fuels, the good gut bacteria begin to:

If you are seriously interested in optimizing your gut health, you can even get yourself a microbiome sequencing that informs you exactly what bacteria are in your gut. Compared to conventional DNA sequencing, this can be a relatively new technology. Nevertheless, researchers are extremely excited about harnessing the wide range of of gut information for disease diagnosis and treatment.

In the not too distant future, it may become commonplace to have personalized nutrition plans and health care predicated on your genes and gut bacteria.

In todays fast-paced society, cognitive technologies like nootropics are well-liked by many people who desire 48 hours out of their day. Unfortunately, boffins have said that there is no strong evidence in synthetic cognitive supplements.

If you still want approaches to boost your productivity, natural compounds, and herbs for health (herbcottage.com) care might be the safer option that really works.

Have you heard of these popular natural cognitive enhancers?

Technology and devices are great for offering valuable data, but that entails that we are constantly bombarded with information. How do we shoot for a balance between performance and burnout?

The answer lies in our biology. Our body has intricate levels of different hormones that try to keep things in balance.

When we have been stressed, the body produces stress hormones like cortisol. The hormone it self is not bad. It actually helps us control blood sugar, metabolism and blood pressure. However, a constantly high level of cortisol could harm both physical and mental health. In women, high cortisol also plays a role in low libido and abnormal menstrual cycles.

But luckily, we have been also naturally equipped with happy hormones like endorphins. These are our natural painkillers that reduce stress and pain. They activate opioid receptors in the brain, but without getting your addicted.

There is not any need for supplements. The most elementary ways of relaxation can perform the trick:

Nourish your social connections

We need to thank the internet and electronic devices for bringing distant people closer. But at the same time, they could also push our close family and friends apart.

Lets not forget that the most primitive and effective way of happiness, even in the era of technology, is genuine human interaction.

The Harvard Medical School reports that people whove great relationships and social support are usually happier and healthier. These include satisfying marriages, family, friends, and community.

In a landmark paper published in the journal Science, researchers found that lack of social connections puts people at increased risk of obesity, smoking, and high blood pressure. In contrast, people who do nourish their social relationships have better longevity, immune system, self-esteem, and additional health advantages.

It may well not sound like a mind-blowing secret, but it is something that all of us forget sometimes. Social connections, just like the body and mind, need to be nourished. We can just only live cheerfully with new technologies whenever we use them for connecting, but not disconnect.

Michael Usiagwu is the CEO of Visible links Pro, apremium Digital Marketing Agency devoted to seeing your brands/company and products gain the right visibility on the internet search engine. He may be reached via [emailprotected]

Link:
Maintaining Perfect Health in the World of New Technologies and Devices - Digital Market News

For a long time now, humans have been looking for the secret to a long and healthy life. Some say it's all about genetics and some associate it with better availability of healthcare facilities. Sure, it is possible for some to be genetically gifted to have a longer life. But genes dont play as huge a role in longevity as your environment and lifestyle.

Studies have shown that people who live more than 100 years have various things in common, the top amongst them being their healthy lifestyle and their positive outlook towards life.

Here are 3 secrets to living a healthy and long life from centenarians (those who have lived beyond 100 years):

1. A healthy diet

A healthy and balanced diet is undoubtedly one of the keys to good health. Experts suggest that a balanced diet should have 7 components - carbs, proteins, unsaturated fats, fibre, vitamins, minerals and water. Water plays a role in various metabolic activities in the body. Make sure you drink at least 8-10 glasses of water a day.

Avoid overeating at all costs since it would promote obesity, which may further increase your risk of various chronic diseases. Instead, follow caloric restriction whenever possible. Caloric restriction is an excellent way to promote longevity. Various studies show the benefits of caloric restriction on health, including one done in Japan that showed how lifetime caloric restriction reduces the risk of diseases and increases lifespan. It can also help you reduce weight.

It is important to note that the term overeating may not mean the same for everyone. Overeating means eating more calories than you need in a day. Daily calorie requirement for different people varies as per their age, sex and physical activity levels. Long term caloric restriction may cause a constant feeling of hunger and low body temperature. So, it is best to talk to a dietician if you are thinking of trying it.

2. Workout regularly

Regular physical activity keeps up your muscle strength, improves your immune system and reduces your risk of chronic diseases including diabetes, heart diseases and cancer. It also improves memory and cognition and can reduce depression and elevate mood.

Experts suggest doing at least 30 minutes of moderate to vigorous activity daily to keep up your health.

However, like every good thing, over-exercising may do more harm than good, especially if you have a health condition. Also, if you dont generally work out, dont jump into the deep end and instead start slowly with a 5-10 minute routine first. Increase the duration and intensity gradually.

3. Be positive

A positive outlook can do miracles for both your mental and physical health. It reduces depression and the risk of diseases. A 35-year-long study done in the USA showed a direct connection between optimism and mortality rate.

On the other hand, stress and anxiety can trigger various pathological conditions. Try and practice mindfulness, breathing exercises and meditation to help reduce stress. Dont hesitate to reach out to your friends and family if you need help

For more information, read our article onBalanced diet chart.

Health articles on News18 are written by myUpchar.com, Indias first and biggest resource for verified medical information. At myUpchar, researchers and journalists work with doctors to bring you information on all things health.

Follow @News18Lifestyle for more

The information provided here is intended to provide free education about certain medical conditions and certain possible treatment. It is not a substitute for examination, diagnosis, treatment, and medical care provided by a licensed and qualified health professional. If you believe you, your child or someone you know suffers from the conditions described herein, please see your health care provider immediately. Do not attempt to treat yourself, your child, or anyone else without proper medical supervision. You acknowledge and agree that neither myUpchar nor News18 is liable for any loss or damage which may be incurred by you as a result of the information provided here, or as a result of any reliance placed by you on the completeness, accuracy or existence of any information provided herein.

Read the rest here:
3 Healthy Habits That Can Help You Live Longer - News18

Global Inherited Metabolic Disorders (IMD) Market: Snapshot

Inherited metabolic disorders (IMD), as the name suggests, are genetic conditions resulting in metabolism issues. The root cause behind maximum cases of inherited metabolic disorders (IMD) is a gene mutation that probably happened a lot many generations back. The mutation in the gene is carried through the generations.

Treatment of inherited metabolic disorders (IMD) consists of dietary supplementation, dietary restrictions, drugs that thwart or regulate metabolism, gene therapy, transplantation of the concerned organ, and dialysis in extreme cases. Currently, the dietary supplements account for a leading position in the global inherited metabolic disorders (IMD) treatment market. Drug manufacturers, however, are slated to come up with more condition-specific therapeutics in the near future.

Get Sample Copy of the Report @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=293

The specificity and high risk affinity of IMD differs from disorder to disorder. Some disorders such as familial cylomicronemia are generally associated closely with Caucasians, while others, namely porphyria is mostly recorded among African Americans. Most of such metabolic disorders are be brought under control with certain changes in the diet and lifestyle of the person. Some inherited metabolic disorders (IMDs) are, however, life threatening. Huntingtons or Zellweger syndrome is to name one such.

The inherited metabolic disorders market lies mostly with the Caucasian and African American populations of world, especially in North America, Europe, Australia, and Africa, followed by the minority populations from South Asia and East A.

At present, genetic screening using mass spectrometry and DNA testing among all newborns are carried out in almost all of the developed nations of the world and also in developing economies of India, Brazil, and China. This helps uncover inherited metabolic disorders (IMD) at an early stage.

GlobalInherited Metabolic Disorders Market: Overview

Globally, IMD affects nearly one in every 2,500 to 5,000 individuals with nearly 300 to 600 new cases found in the U.K., according to Public Health Genetics U.K. The specificity and high risk affinity of IMD varies from disorder to disorder, with some disorders like familial cylomicronemia being closely associated with Caucasians and others like porphyria being recoded largely among African Americans. These metabolic disorders are often controllable with certain lifestyle and diet changes, including Familial Cylomicronemia and Phenylketonuria. But some IMDs are highly dangerous and may affect the survivability of a person, such as Huntingtons or Zellweger syndrome.

A lot of IMDs arise when the mutated gene responsible is inherited by the natural selection process and a large number of these genes are recessive. This is probably why a large number of these metabolic disorders are rare occurrences, whereas certain other genes are dominant in nature; this makes it difficult for a willing parent to conceive a child as the risk for transferring a gene remains high (e.g. Huntingtons). Familial chylomicronemia occurs when an individual genetically inherits Lipoprotein lipase enzyme mutation. This is a very rare genetic disease at occurrence rate of 1 individual per million with chances of symptoms occurring only in homozygous individuals (receiving mutation genes from both parents) or in other words recessive gene transmission.

Request TOC of the Report @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=293

GlobalInherited Metabolic Disorders Market: Current Market Trends

Nowadays, genetic screening via mass spectrometry and DNA testing of all newborn children are done in nearly all of the developed countries and also some developing countries of the world, including India, China, and Brazil, albeit across a small percentage of the national population. This prepares a parent and the child with the necessary precautions and treatment for increasing the longevity of the concerned newborn. The life expectancy of such a child with all the necessary care and precaution is at par with the average individual.

However among many adult populations and in some children, rare genetic metabolic disorders are abruptly presented and often not accurately diagnosed. In such individuals, abnormal metabolic changes are considered to be a type of genetic mutation in routine diagnosis. Symptoms such as growth failure, precocious puberty and development delay in children below 12, and anemia, neurological disorder, cancer, muscle weakness, rapid hormonal changes, and skin changes in adults, are regarded to probably have a genetic metabolic cause.

GlobalInherited Metabolic Disorders Market: Treatment Classifications

The treatment of IMDs is broadly classified into dietary restrictions, dietary supplementation, drugs that inhibit or regulate metabolism, transplantation of the concerned organ, gene therapy, and dialysis in severe cases. In the case of familial cylomicronemia, gene therapy includes Alipogene tiparvovec recombinant gene therapy drug, manufactured by UniQure Inc. This therapy utilizes viruses (adenovirus vector) designed in such a way that upon infection, the gene for producing the lipoprotein lipase is induced into the host cell, thereby producing the enzyme in-vivo. This therapy has shown positive results and is expected to be released into the market soon. For now, the global inherited metabolic disorders Market lies broadly in the dietary supplements market.

Read Comprehensive Overview of Report @https://www.tmrresearch.com/inherited-metabolic-disorders-market

Go here to see the original:
Inherited Metabolic Disorders (IMD) Market Promising Growth Opportunities and Forecast 2017-2025 - Daily Research Chronicles

Integrated Health System is bringing cell and gene therapy to cats, dogs, and horses. Recently IHS Pets has helped a paralyzed dog with a spinal cord injury to walk again after it was treated with experimental PRP and prolotherapy. Click here to see the video.

Telomeres

Aging is the root of virtually every complex noncommunicable disease in humans and animals. Telomeres are the protective end caps on the ends of our chromosomes, they are as important for the health of both humans and our pets, and they play roles in longevity.

One of the contributing factors in the lifespan in dog breeds is telomere length. As in humans researchers have found that telomere length is a strong predictor of average life span among 15 different breeds consistent with telomeres playing a role in life span determination. Dogs lose telomeric DNA ~10-fold faster than humans, which is similar to the ratio of average life spans between these species. As such telomerase therapy may be beneficial to pets as well as their human caretakers.

Telomerase gene therapy has been shown to extend lifespan in animals, this therapy may help to increase bone mineral density, improve motor performance, improve metabolism, and improve brain function.

Follistatin

The loss of muscle mass with age is just as problematic for animals as it is to humans; in cats for instance a study showed that for each 100g loss of lean body mass increased the risk of death by 20%. This is typically accompanied by frailty, and it is a contributing factor to metabolic syndrome, diabetes, heart disease, and overall mortality.

Diet and exercise have been shown to pay key roles in keeping pets healthy, but the loss of muscle mass is unavoidable without an effective intervention. Enter follistatin: myostatin blocks muscle growth, when it is inhibited then follistatin is able to let muscles grow freely to stop them from wasting away.

Follistatin gene therapy has been shown to be safe and effective in animals, this therapy may help to protect against frailty, increase muscle density, increase strength, and increase endurance.

Klotho: The Queen of Anti-Aging Proteins

1 in 3 cats will suffer from renal disease, but these numbers are under scrutiny with some suggesting that estimate may be too conservative. Chronic kidney failure can occur gradually over months or years, and it is one of the most common conditions affecting older cats with most cases progressing over time worsening the disease.

Klotho is known to play a significant role in the development of chronic kidney disease, and researchers are now turning to its broader role in the anging process as a whole; such as induces expression with gene therapy in mice has been shown to extend lifespan by targeting many of the same pathways as caloric restriction. Blocking Klotho has been shown to cause premature aging.

Klotho also helps to protect the brain, and contributes to more differences in intelligence than any one single gene. Research from the University of California has shown it to protect the brains of mice and improve brain function within 4 hours; and this result included young mice, old mice, and those that were models of Alzheimers disease.

In addition Klotho also plays a critical role in the inflammaging process. Inflammaging is the long term result of the chronic physiological stimulation of the innate immune system which can become damaging during the aging process.

Circulating levels of Kloto decreases with age, this decrease is associated with an increased risk of age related disease. Gene therapy with Klotho has been shown to increase lifespan in animal models, and it may improve kidney function, brain function, clear damage caused by oxidative stress, and protect against cardiovascular disease.

With the remarkable progress being made in genetics, gene therapy may play increasingly prominent and transformative roles in medicine for both humans and animals due to the potential to treat diseases and congenital disorders.

Pets can be an important part of life, they calm us, make us laugh, and create a bond of unconditional love. The company does note that all therapies are experimental, they are not approved by any regulatory body, and they make no claims that outcomes will be positive or beneficial.

IHS Pets is the veterinary wing of Integrated Health Systems, BioViva Sciences exclusive partner. IHS connects with doctors and patients who are interested in the power of gene therapy to pave the way to healthy aging and longevity.

Continued here:
IHS Pets: Bringing Cell And Gene Therapy To Cats, Dogs & Horses - Anti Aging News

Several new genes linked to an exceptionally long life have been discovered, according to a new study that examined the genomes of people living into their 100s, known as centenarians.

Using a new method, the researchers found four genes linked with a very long life: A gene called ABO, which is involved in determining blood type; a gene called CDKN2B, which regulates cell division; a gene called APOE, which is linked with Alzheimer's disease; and a gene called SH2B3, which was previously found to extend life in fruit flies.

The researchers hope that future studies will uncover even more genes linked with longevity, and figure out how these genes may affect the aging process.

"There's a reasonably strong genetic component to becoming a centenarian, and we want to find out what that is," said study researcher Stuart Kim, a professor in the Department of Developmental Biology and Genetics at Sanford University. "We're beginning to unravel the mystery" of why some people age so successfully compared to the normal population, Kim said. [Extending Life: 7 Ways to Live Past 100]

Previous studies have attempted to find variations in genes that are more common in the very old compared with younger people, but haven't had much luck. These studies looked through millions of variations in the human genome, but they might have missed some important associations.

The new study aimed to narrow the search for genes linked with long life by focusing on ones that are known to strongly affect a person's risk of age-related disease, like heart disease and Alzheimer's. The thinking is that these diseases increase a person's risk of dying early, and so genetic variants that increase the risk of these diseases would also decrease the chances of a long life, the researchers said.

The researchers first searched for longevity-linked genes in a population of about 800 people over age 100 and 5,400 people over age 90.

They found eight genes that were linked with a long life span, and were able to confirm four of these genes in a follow-up analysis of about 1,000 people ages 100 or over.

The study found that certain variants in the ABO, CDKN2B, APOE and SH2B3 genes were more common in centenarians than in people with a typical life span. (Adults in the United States have an average life expectancy of about 79 years, according to the Centers for Disease Control and Prevention.)

For example, the study found that the a genetic variation associated with type O blood was more common in centenarians than in the study's control group, meaning that there were slightly more centenarians with type O blood, compared to people with a typical life span. Previous studies have found that people with type O blood have a lower risk of coronary heart disease and cancer, and have lower cholesterol levels than people with other blood types.

Another genetic variant in the CDKN2B gene seems to play a role in whether cells continue to divide, or stop dividing. Given that the stoppage of cell division, called senescence, is thought to contribute to aging, having a gene variation that reduces cell senescence could be a factor that contributes to successful aging, Kim said.

Kim suspects that there are still more genes linked with a longer life span.

"I hope our paper inspires other people to continue searching for" genes linked with longevity, Kim said.

The study was published yesterday (Dec. 17) in the journal PLOS Genetics.

Follow Rachael Rettner @RachaelRettner. FollowLive Science @livescience, Facebook& Google+. Original article on Live Science.

Originally posted here:
Living to 100: New Genes for Longevity Found | Live Science

Have you ever wondered how long you might live? New research suggests that an important indicator of your probable life span may be your genes. Scientists have identified unique genetic signatures strongly associated with a long and healthy life, findings that could help to further the understanding of how certain genes may offer protection from common age-related diseases like cancer, dementia and cardiovascular disease. And one day the data might lead to the development of genetic tests to predict whether a person can expect to live into old age as well as guide intervention efforts to prevent age-related illness.

The study, led by Paola Sebastiani, professor of biostatistics at Boston University (B.U.) School of Pubic Health, and Thomas Perls, professor of medicine and geriatrics at the B.U. School of Medicine, was published online July 1 in Science.

A person's life span is thought to be largely determined by the combined effects of genetics and environmental factors. Twin studies, however, suggest genetics only account for approximately 20 to 30 percent of an individual's chance of surviving to age 85.

Lifestyle choices, particularly diet, exercise and smoking habits, play an undisputed role in determining not only how long one will live, but also how well one ages. Studies show that Seventh-Day Adventists, whose church encourages behaviors that promote healthy aging, have a well-documented average life span of 88 years, approximately eight years longer than the average U.S. citizen. For the most part, Adventists exercise regularly, are vegetarian, and don't smoke or drink alcohol.

Nevertheless, a glance at your family tree may indicate whether you have a familial tendency toward longevity. Research suggests that exceptional longevity (EL)living one to three decades beyond the average U.S. life span of approximately 80 yearsruns strongly in families. "Thathas always made us believe that genetics is playing a very important role in this wonderful trait," Perls said Wednesday in a press conference.

Genetic factors can contribute to the degree of longevity in at least two important ways: An individual may inherit certain genetic variations that predispose him or her to disease that decreases longevity; other gene variants may confer disease resistance, thereby increasing it.

To better understand the genetic components of longevity, the researchers analyzed the DNA of more than 800 subjects between the ages of 95 to 119 and compared it with DNA from random controls. The genome-wide survey identified specific genetic variations, or SNPs (single-nucleotide polymorphisms), that were associated with the longevity group.

Next, the researchers developed a genetic model comprising 150 SNPs in order to compute the predisposition of an individual toward EL. Their model successfully predicted exceptional longevity in a different sample of centenarians (individuals that live to age 100) with 77 percent accuracy. This demonstrates that EL is strongly associated with complex combinations of genetic variants.

The researchers found that, based on subjects' genetic profiles, the centenarians could be further divided into 19 subgroups, some of which were associated with delayed onset of age-related diseases such as dementia, hypertension and cardiovascular disease. These signatures represent different genetic paths to age 100 and beyond, Sebastiani said in the press conference.

"Centenarians are indeed a model of aging well," Perls said. Previous work has shown that 90 percent of centenarians are disability-free at the age of 93. In industrialized nations approximately one out of every 6,000 people lives beyond the age of 100. Supercentenarians, or individuals that are older than 110, are even rareronly one in seven million fall into this category.

Surprisingly, the researchers found that approximately 15 percent of control subjects also had the genetic signature associated with longevity. This suggests that many more people have the genetic potential to survive into old age than previously thought. "We know a lot about the human genome, but we also know that there is a lot that remains to be discovered," Sebastiani said. "Genetics is fundamental in EL, but it's not the only thing. So there may be other factors like environment or other lifestyles that may help people live longer and healthier lives," he added.

Importantly, there was no difference in the presence of known disease-associated gene variants between the longevity and control groups. The researchers conclude that EL may result from an enrichment of longevity-associated gene variants that may counteract the effects of having a disease-associated gene.

"I think this is a step towards making sense out of a lot of datagenetic data, environmental data, epidemiological datato help us understand factors that contribute to long and healthy life," says Winifred Rossi, deputy director of the Division of Geriatrics and Clinical Gerontology at the National Institute on Aging, who wasn't involved in the study.

"We're starting to get to the point where it might be possible to use the information about these variants to predict someone's likelihood of achieving EL," says Matt Kaeberlein, professor of pathology at the University of Washington in Seattle, also not involved in the study. He added that the challenge was to next move beyond this correlative study to figure out how these gene variations may lead to functional changes that contribute to the molecular process of aging.

The authors caution that further study and replication of their results in different populations is needed to verify their model before it will be useful for individual genetic testsor before longevity "cocktails" are created.

"My hope has always been with the study that we would learn much more about how to get lots of people to live to older age in good health and markedly delay their disability and age of onset of diseases," Perls said. "I look at the complexity of this puzzle and feel very strongly that this will not lead to treatments that will get a lot of people to become centenarians, but rather will make a dent in the onset of age-related diseases like Alzheimer's, for example."

More:
Live Long and Proper: Genetic Factors Associated with ...

In 2013, Google cofounder and CEO Larry Page announced the formation of a new Alphabet entity dedicated to solving the pesky puzzle of mortality. Since then, the billion-dollar longevity lab known as Calicoshort for California Life Companyhas been trying to tease apart the fundamental biology of aging in the hopes of one day defeating death. The hyper-secretive research venture has released few details about what it actually does inside its Silicon Valley lab, but there have been hints. One of the companys first hires was renowned geneticist Cynthia Kenyon, a UC San Francisco researcher who 20 years ago doubled the lifespan of a lab roundworm by flipping a single letter in its DNA.

Shortly after joining Calico, Kenyon recruited a UCSF bioinformatics postdoc named Graham Ruby. He didnt want to dig into worm genetics or study the companys colony of long-lived naked mole rats. He wanted to first ask a much broader question: how big a role do genes play, anyway, in determining how long someone lives? Other scientists had tried to ask that question before, with conflicting results. To clear things up would require getting much, much more data. So Calico went to the biggest family history database in the world: the consumer genetics and genealogy firm Ancestry.

In 2015, the companies inked a research partnership to investigate the human heredity of lifespan, with Ruby leading the charge to sift through Ancestrys vast forest of family trees. What he found by analyzing the pedigrees of more than 400 million people who lived and died in Europe and America going back to 1800 was that although longevity tends to run in families, your DNA has far less influence on how long you live than previously thought. The results, published Tuesday in the journal Genetics, is the first research to be made public from the collaboration, which ended quietly in July and whose terms remain confidential.

The true heritability of human longevity for that cohort is likely no more than seven percent, says Ruby. Previous estimates for how much genes explain variations in lifespan have ranged from around 15 to 30 percent. So what did Ruby uncover that previous studies had missed? Just how often amorous humans go against the old adage that opposites attract.

It turns out that through every generation, people are much more likely to select mates with similar lifespans than random chance would predict. The phenomenon, called assortative mating, could be based on genetics, or sociocultural traits, or both. For example, you might choose a partner who also has curly hair, and if the curly-haired trait winds up being somehow associated with long lifespans, this would inflate estimates of lifespan heritability passed on to your kids. Same thing for non-genetic traits like wealth, education, and access to good health care. People tend to choose partners in their same income bracket with the same terminal degree, both of which are associated with living longer, healthier lives.

The first hint that something other than genetics or a shared family environment might be at work came when Ruby tried looking at in-law relatives. His analysis started with a set of family trees comprising 400 million individuals. The data had been cleaned, de-identified, and stitched together by genealogists and computer scientists at Ancestry based on subscriber-generated public information. Using the basic laws of heredityeveryone inherits half their DNA from one parent and half from the other, repeated across generationsRubys team looked at how related two people were and how long they lived. They investigated parent-child pairs, sibling pairs, various cousins, and so on. Nothing much surprising popped out there.

See original here:
The Key to a Long Life Has Little to Do With Good Genes

Adrenomyeloneuropathy Treatment

In a recent study published by QY Research, titled Global Adrenomyeloneuropathy Treatment MarketResearch Report, analysts offer an in-depth analysis of the global Adrenomyeloneuropathy Treatment market. The study analyzes the various aspects of the market by studying its historic and forecast data. The research report provides a Porters five force model, SWOT analysis, and PESTEL analysis of the Adrenomyeloneuropathy Treatment market. The different areas covered in the report are Adrenomyeloneuropathy Treatment market size, drivers and restraints, segment analysis, geographic outlook, major manufacturers in the market, competitive landscape, value/volume data, marketing strategies, and expert views

Major Key Player operating in this report are: Ascend Biopharmaceuticals, Novadip Biosciences, Eureka Therapeutics, Human Longevity, Regeneus, Allogene Therapeutics, BioRestorative Therapies, Immatics Biotechnologies, NewLink Genetics, Cytori Therapeutics, Talaris Therapeutics Adrenomyeloneuropathy Treatment

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1654351/global-adrenomyeloneuropathy-treatment-market

Segmental Analysis

The report has classified the global Adrenomyeloneuropathy Treatment industry into segments including product type and application. Every segment is evaluated based on growth rate and share. Besides, the analysts have studied the potential regions that may prove rewarding for the Adrenomyeloneuropathy Treatment manufacturers in the coming years. The regional analysis includes reliable predictions on value and volume, thereby helping market players to gain deep insights into the overall Adrenomyeloneuropathy Treatment industry.

Global Adrenomyeloneuropathy Treatment Market Segment By Type:

End Users, Hospitals, Clinics, Ambulatory Surgical Centers, Others

Global Adrenomyeloneuropathy Treatment Market Segment By Application:

Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Adrenomyeloneuropathy Treatment market in 2020. COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future. This report also analyses the impact of Coronavirus COVID-19 on the Adrenomyeloneuropathy Treatment industry. Based on our recent survey, we have several different scenarios about the Adrenomyeloneuropathy Treatment YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ xx million in 2019. The market size of Adrenomyeloneuropathy Treatment will reach xx in 2026, with a CAGR of xx% from 2020 to 2026. With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Adrenomyeloneuropathy Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Adrenomyeloneuropathy Treatment market in terms of revenue. Players, stakeholders, and other participants in the global Adrenomyeloneuropathy Treatment market will be able to gain the upper hand as they use the report as a powerful resource. For this version of the report, the segmental analysis focuses on revenue and forecast by each end users segment in terms of revenue and forecast by each therapy segment in terms of revenue for the period 2015-2026. Regional and Country-level Analysis The report offers an exhaustive geographical analysis of the global Adrenomyeloneuropathy Treatment market, covering important regions, viz, North America, Europe, China and Australia. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc. The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each end users segment in terms of revenue for the period 2015-2026. Competition Analysis In the competitive analysis section of the report, leading as well as prominent players of the global Adrenomyeloneuropathy Treatment market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020. On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Adrenomyeloneuropathy Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Adrenomyeloneuropathy Treatment market. The following players are covered in this report:, Ascend Biopharmaceuticals, Novadip Biosciences, Eureka Therapeutics, Human Longevity, Regeneus, Allogene Therapeutics, BioRestorative Therapies, Immatics Biotechnologies, NewLink Genetics, Cytori Therapeutics, Talaris Therapeutics Adrenomyeloneuropathy Treatment Breakdown Data by Therapy, Steroid Replacement Therapy, Stem Cell Transplant Adrenomyeloneuropathy Treatment Breakdown Data by End Users, Hospitals, Clinics, Ambulatory Surgical Centers, Others

In terms of region, this research report covers almost all the major regions across the globe such as North America, Europe, South America, the Middle East, and Africa, and the Asia Pacific. Europe and North America regions are anticipated to show an upward growth in the years to come. While Adrenomyeloneuropathy Treatment market in Asia Pacific regions is likely to show remarkable growth during the forecasted period. Cutting edge technology and innovations are the most important traits of the North America region and thats the reason most of the time the US dominates the global markets. The keyword market in the South, America region is also expected to grow in the near future.

Competitive Landscape

It is important for every market participant to be familiar with the competitive scenario in the global Adrenomyeloneuropathy Treatment industry. In order to fulfil the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.

Key companies operating in the global Adrenomyeloneuropathy Treatment market include: Ascend Biopharmaceuticals, Novadip Biosciences, Eureka Therapeutics, Human Longevity, Regeneus, Allogene Therapeutics, BioRestorative Therapies, Immatics Biotechnologies, NewLink Genetics, Cytori Therapeutics, Talaris Therapeutics Adrenomyeloneuropathy Treatment

Key questions answered in the report:

What is the growth potential of the Adrenomyeloneuropathy Treatment market?

Which product segment will grab a lions share?

Which regional market will emerge as a frontrunner in the coming years?

Which application segment will grow at a robust rate?

What are the growth opportunities that may emerge in the Adrenomyeloneuropathy Treatment industry in the years to come?

What are the key challenges that the global Adrenomyeloneuropathy Treatment market may face in the future?

Which are the leading companies in the global Adrenomyeloneuropathy Treatment market?

Which are the key trends positively impacting the market growth?

Which are the growth strategies considered by the players to sustain hold in the global Adrenomyeloneuropathy Treatment market

Reasons to buy this report:

QY Research report is designed in a method that assists clients to acquire a complete knowledge of the overall market scenario and the important sectors.

This report consists of a detailed overview of market dynamics and comprehensive research.

Explore further market opportunities and identify high potential categories based on detailed volume and value analysis

Detail information on competitive landscape, recent market trends and changing technologies that can be useful for the companies which are competing in this market

Gaining knowledge about competitive landscape based on detailed brand share analysis to plan an effective market positioning

Enquire Customization in the Report

https://www.qyresearch.com/customize-request/form/1654351/global-adrenomyeloneuropathy-treatment-market

Finally, the global Adrenomyeloneuropathy Treatment Market is a valuable source of guidance for individuals and companies. One of the major reasons behind providing market attractiveness index is to help the target audience and clients to identify the several market opportunities in the global Adrenomyeloneuropathy Treatment market. Moreover, for a better understanding of the market, QY Research has also presented a key to get information about various segments of the global Adrenomyeloneuropathy Treatment market.

Table of content

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered: Ranking by Adrenomyeloneuropathy Treatment Revenue1.4 Market Analysis by Therapy1.4.1 Global Adrenomyeloneuropathy Treatment Market Size Growth Rate by Therapy: 2020 VS 20261.4.2 Steroid Replacement Therapy1.4.3 Stem Cell Transplant1.5 Market by End Users1.5.1 Global Adrenomyeloneuropathy Treatment Market Share by End Users: 2020 VS 20261.5.2 Hospitals1.5.3 Clinics1.5.4 Ambulatory Surgical Centers1.5.5 Others1.6 Coronavirus Disease 2019 (Covid-19): Adrenomyeloneuropathy Treatment Industry Impact1.6.1 How the Covid-19 is Affecting the Adrenomyeloneuropathy Treatment Industry1.6.1.1 Adrenomyeloneuropathy Treatment Business Impact Assessment Covid-191.6.1.2 Supply Chain Challenges1.6.1.3 COVID-19s Impact On Crude Oil and Refined Products1.6.2 Market Trends and Adrenomyeloneuropathy Treatment Potential Opportunities in the COVID-19 Landscape1.6.3 Measures / Proposal against Covid-191.6.3.1 Government Measures to Combat Covid-19 Impact1.6.3.2 Proposal for Adrenomyeloneuropathy Treatment Players to Combat Covid-19 Impact 1.7 Study Objectives 1.8 Years Considered 2 Global Growth Trends by Regions2.1 Adrenomyeloneuropathy Treatment Market Perspective (2015-2026)2.2 Adrenomyeloneuropathy Treatment Growth Trends by Regions2.2.1 Adrenomyeloneuropathy Treatment Market Size by Regions: 2015 VS 2020 VS 20262.2.2 Adrenomyeloneuropathy Treatment Historic Market Share by Regions (2015-2020)2.2.3 Adrenomyeloneuropathy Treatment Forecasted Market Size by Regions (2021-2026) 2.3 Industry Trends and Growth Strategy 2.3.1 Market Top Trends 2.3.2 Market Drivers2.3.3 Market Challenges2.3.4 Porters Five Forces Analysis2.3.5 Adrenomyeloneuropathy Treatment Market Growth Strategy2.3.6 Primary Interviews with Key Adrenomyeloneuropathy Treatment Players (Opinion Leaders) 3 Competition Landscape by Key Players3.1 Global Top Adrenomyeloneuropathy Treatment Players by Market Size3.1.1 Global Top Adrenomyeloneuropathy Treatment Players by Revenue (2015-2020)3.1.2 Global Adrenomyeloneuropathy Treatment Revenue Market Share by Players (2015-2020)3.1.3 Global Adrenomyeloneuropathy Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.2 Global Adrenomyeloneuropathy Treatment Market Concentration Ratio3.2.1 Global Adrenomyeloneuropathy Treatment Market Concentration Ratio (CR5 and HHI)3.2.2 Global Top 10 and Top 5 Companies by Adrenomyeloneuropathy Treatment Revenue in 20193.3 Adrenomyeloneuropathy Treatment Key Players Head office and Area Served3.4 Key Players Adrenomyeloneuropathy Treatment Product Solution and Service3.5 Date of Enter into Adrenomyeloneuropathy Treatment Market3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Therapy (2015-2026)4.1 Global Adrenomyeloneuropathy Treatment Historic Market Size by Therapy (2015-2020)4.2 Global Adrenomyeloneuropathy Treatment Forecasted Market Size by Therapy (2021-2026) 5 Adrenomyeloneuropathy Treatment Breakdown Data by End Users (2015-2026)5.1 Global Adrenomyeloneuropathy Treatment Market Size by End Users (2015-2020)5.2 Global Adrenomyeloneuropathy Treatment Forecasted Market Size by End Users (2021-2026) 6 North America6.1 North America Adrenomyeloneuropathy Treatment Market Size (2015-2020)6.2 Adrenomyeloneuropathy Treatment Key Players in North America (2019-2020)6.3 North America Adrenomyeloneuropathy Treatment Market Size by Therapy (2015-2020)6.4 North America Adrenomyeloneuropathy Treatment Market Size by End Users (2015-2020) 7 Europe7.1 Europe Adrenomyeloneuropathy Treatment Market Size (2015-2020)7.2 Adrenomyeloneuropathy Treatment Key Players in Europe (2019-2020)7.3 Europe Adrenomyeloneuropathy Treatment Market Size by Therapy (2015-2020)7.4 Europe Adrenomyeloneuropathy Treatment Market Size by End Users (2015-2020) 8 China8.1 China Adrenomyeloneuropathy Treatment Market Size (2015-2020)8.2 Adrenomyeloneuropathy Treatment Key Players in China (2019-2020)8.3 China Adrenomyeloneuropathy Treatment Market Size by Therapy (2015-2020)8.4 China Adrenomyeloneuropathy Treatment Market Size by End Users (2015-2020) 9 Australia9.1 Australia Adrenomyeloneuropathy Treatment Market Size (2015-2020)9.2 Adrenomyeloneuropathy Treatment Key Players in Australia (2019-2020)9.3 Australia Adrenomyeloneuropathy Treatment Market Size by Therapy (2015-2020)9.4 Australia Adrenomyeloneuropathy Treatment Market Size by End Users (2015-2020) 10Key Players Profiles10.1 Ascend Biopharmaceuticals10.1.1 Ascend Biopharmaceuticals Company Details10.1.2 Ascend Biopharmaceuticals Business Overview and Its Total Revenue10.1.3 Ascend Biopharmaceuticals Adrenomyeloneuropathy Treatment Introduction10.1.4 Ascend Biopharmaceuticals Revenue in Adrenomyeloneuropathy Treatment Business (2015-2020))10.1.5 Ascend Biopharmaceuticals Recent Development10.2 Novadip Biosciences10.2.1 Novadip Biosciences Company Details10.2.2 Novadip Biosciences Business Overview and Its Total Revenue10.2.3 Novadip Biosciences Adrenomyeloneuropathy Treatment Introduction10.2.4 Novadip Biosciences Revenue in Adrenomyeloneuropathy Treatment Business (2015-2020)10.2.5 Novadip Biosciences Recent Development10.3 Eureka Therapeutics10.3.1 Eureka Therapeutics Company Details10.3.2 Eureka Therapeutics Business Overview and Its Total Revenue10.3.3 Eureka Therapeutics Adrenomyeloneuropathy Treatment Introduction10.3.4 Eureka Therapeutics Revenue in Adrenomyeloneuropathy Treatment Business (2015-2020)10.3.5 Eureka Therapeutics Recent Development10.4 Human Longevity10.4.1 Human Longevity Company Details10.4.2 Human Longevity Business Overview and Its Total Revenue10.4.3 Human Longevity Adrenomyeloneuropathy Treatment Introduction10.4.4 Human Longevity Revenue in Adrenomyeloneuropathy Treatment Business (2015-2020)10.4.5 Human Longevity Recent Development10.5 Regeneus10.5.1 Regeneus Company Details10.5.2 Regeneus Business Overview and Its Total Revenue10.5.3 Regeneus Adrenomyeloneuropathy Treatment Introduction10.5.4 Regeneus Revenue in Adrenomyeloneuropathy Treatment Business (2015-2020)10.5.5 Regeneus Recent Development10.6 Allogene Therapeutics10.6.1 Allogene Therapeutics Company Details10.6.2 Allogene Therapeutics Business Overview and Its Total Revenue10.6.3 Allogene Therapeutics Adrenomyeloneuropathy Treatment Introduction10.6.4 Allogene Therapeutics Revenue in Adrenomyeloneuropathy Treatment Business (2015-2020)10.6.5 Allogene Therapeutics Recent Development10.7 BioRestorative Therapies10.7.1 BioRestorative Therapies Company Details10.7.2 BioRestorative Therapies Business Overview and Its Total Revenue10.7.3 BioRestorative Therapies Adrenomyeloneuropathy Treatment Introduction10.7.4 BioRestorative Therapies Revenue in Adrenomyeloneuropathy Treatment Business (2015-2020)10.7.5 BioRestorative Therapies Recent Development10.8 Immatics Biotechnologies10.8.1 Immatics Biotechnologies Company Details10.8.2 Immatics Biotechnologies Business Overview and Its Total Revenue10.8.3 Immatics Biotechnologies Adrenomyeloneuropathy Treatment Introduction10.8.4 Immatics Biotechnologies Revenue in Adrenomyeloneuropathy Treatment Business (2015-2020)10.8.5 Immatics Biotechnologies Recent Development10.9 NewLink Genetics10.9.1 NewLink Genetics Company Details10.9.2 NewLink Genetics Business Overview and Its Total Revenue10.9.3 NewLink Genetics Adrenomyeloneuropathy Treatment Introduction10.9.4 NewLink Genetics Revenue in Adrenomyeloneuropathy Treatment Business (2015-2020)10.9.5 NewLink Genetics Recent Development10.10 Cytori Therapeutics10.10.1 Cytori Therapeutics Company Details10.10.2 Cytori Therapeutics Business Overview and Its Total Revenue10.10.3 Cytori Therapeutics Adrenomyeloneuropathy Treatment Introduction10.10.4 Cytori Therapeutics Revenue in Adrenomyeloneuropathy Treatment Business (2015-2020)10.10.5 Cytori Therapeutics Recent Development10.11 Talaris Therapeutics10.11.1 Talaris Therapeutics Company Details10.11.2 Talaris Therapeutics Business Overview and Its Total Revenue10.11.3 Talaris Therapeutics Adrenomyeloneuropathy Treatment Introduction10.11.4 Talaris Therapeutics Revenue in Adrenomyeloneuropathy Treatment Business (2015-2020)10.11.5 Talaris Therapeutics Recent Development 11Analysts Viewpoints/Conclusions 12Appendix12.1 Research Methodology12.1.1 Methodology/Research Approach12.1.2 Data Source12.2 Disclaimer12.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from a huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Follow this link:
Adrenomyeloneuropathy Treatment Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026|Novadip Biosciences, Eureka...

News can be fascinating or frightening. Researchers have managed to hack into evolution by accelerating the transformation of the apes brain into a human-like brain thanks to a gene that increases the number of neural stem cells. The experiment was stopped for ethical reasons, but it still raises many questions about this kind of manipulation.

There are 95% of similarities between humans and chimpanzees. The human genome is therefore very similar to that of certain animals.

What if, thanks to genetic manipulation, apes became as intelligent as humans and competed with them as they did on the Planet of the Apes? The subject has fascinated scientists for years, and a new experiment brings us a little closer to Pierre Boules book, adapted for the cinema in 1968. German and Japanese researchers claim to have hacked into the evolution of the brain by increasing the volume of the neocortex in marmoset embryos.

Seven million years separate the great apes from the first Homo sapiens. A slow development led to an increase in the brain size and changes in its structure, including an increase in the cerebral neocortex. The latter, the youngest part of the cerebral cortex during evolution, is about three times the size of our closest relative, the chimpanzee. It is at the center of cognitive functions such as logical thinking and language. One of the key questions for scientists is how the neocortex was able to become so large and give us our cognitive abilities.

In the study published in the journal Science, Wieland Huttner and his colleagues at the Max Planck Institute for Cell Biology and Molecular Genetics (MPI-CBG) in Dresden have investigated the ARHGAP11B gene. The ARHGAP11B gene is the result of a mutation in the ARHGAP11A gene that occurred approximately 1.5 million years ago along the evolutionary line that led to todays Neanderthals, Denisovans, and humans after the line of descent separated from that of the chimpanzee. This gene encodes a protein known for its ability to increase the production of neural stem cells.

Read Also: Genetics Have Less Effect on Longevity, Calico Study Shows

The mutation in the ARHGAP11B gene from a single C to a G gene letter results in the loss of 55 nucleotides in the formation of the corresponding messenger RNA. This leads to a change in the transcription of the proteins amino acids, explains Wieland Huttner. This mutation seems to have directly influenced human evolution, he adds. By 2015, Huttner had succeeded in increasing the production of brain stem cells in mice, but with a boosted version of the gene. This time, German researchers joined forces with the Central Institute for Experimental Animals (CIEA) in Kawasaki and Keio University in Tokyo, pioneers in the creation of transgenic monkeys, to conduct an experiment with the normal version of the human gene in marmoset fetuses.

A larger, brain with more folding

The gene was implanted into Mykot embryos three to five days after ovulation. They then allowed the embryos to live to 101 days, 50 days before the normal date of birth. This allowed them to see three important developments in the development of the monkey brain:

Read Also: How Your Smartphone Can Reduce Your Brain Power and Harm Your Health

From here to the creation of monkeys that are so intelligent and competitive to humans, many hurdles have to still be overcome. However, to avoid any controversy, the researchers have taken all ethical precautions. It is not a question of working on apes or chimpanzees that are too close to humans, or of completing the birth of genetically modified apes. Wieland Huttner also hints at criticism of the Chinese experiment. It would have been irresponsible to complete the birth of the marmosets because the behavioral changes caused by the alteration of the neocortex are not known, says Huttner. So for the moment, we will not know whether these marmosets could have played chess with us.

Human-specific ARHGAP11B increases size and folding of primate neocortex in the fetal marmoset

Here is the original post:
Planet of the Apes: by Enlarging the Brains of Apes Are Scientists Creating Worthy Opponents to Humans - Gilmore Health News

The causes of aging are extremely complex and unclear. But with longevity clinical trials increasing, more answersand questionsare emerging than ever before.

With the dramatic demonetization of genome reading and editing over the past decade, and Big Pharma, startups, and the FDA starting to face aging as a disease, we are starting to turn those answers into practical ways to extend our healthspan.

In this article, Ill explore how genome sequencing and editing, along with new classes of anti-aging drugs, are augmenting our biology to further extend our healthy lives.

Your genome is the software that runs your body. A sequence of 3.2 billion letters makes you you. These base pairs of As, Ts, Cs, and Gs determine your hair color, your height, your personality, your propensity for disease, your lifespan, and so on.

Until recently, its been very difficult to rapidly and cheaply read these lettersand even more difficult to understand what they mean. Since 2001, the cost to sequence a whole human genome has plummeted exponentially, outpacing Moores Law threefold. From an initial cost of $3.7 billion, it dropped to $10 million in 2006, and to $1,500 in 2015.

Today, the cost of genome sequencing has dropped below $600, and according to Illumina, the worlds leading sequencing company, the process will soon cost about $100 and take about an hour to complete.

This represents one of the most powerful and transformative technology revolutions in healthcare. When we understand your genome, well be able to understand how to optimize you.

In addition to reading the human genome, scientists can now edit a genome using a naturally occurring biological system discovered in 1987 called CRISPR/Cas9.

Short forClusteredRegularlyInterspacedShortPalindromicRepeats andCRISPR-associated protein9, the editing system was adapted from a naturally-occurring defense system found in bacteria.

Heres how it works. The bacteria capture snippets of DNA from invading viruses (or bacteriophage) and use them to create DNA segments known as CRISPR arrays. The CRISPR arrays allow the bacteria to remember the viruses (or closely related ones), and defend against future invasions. If the viruses attack again, the bacteria produce RNA segments from the CRISPR arrays to target the viruses DNA. The bacteria then use Cas9 to cut the DNA apart, which disables the virus.

Most importantly, CRISPR is cheap, quick, easy to use, and more accurate than all previous gene editing methods. As a result, CRISPR/Cas9 has swept through labs around the world asthe way to edit a genome. A short search in the literature will show an exponential rise in the number of CRISPR-related publications and patents.

Early results are impressive. Researchers have used CRISPR to genetically engineer cocaine resistance into mice, reverse the gene defect causing Duchenne muscular dystrophy (DMD) in dogs, and reduce genetic deafness in mice.

Already this year, CRISPR-edited immune cells have been shown to successfully kill cancer cells in human patients. Researchers have discovered ways to activate CRISPR with light and use the gene-editing technology to better understand Alzheimers disease progression.

With great power comes great responsibility, and the opportunity for moral and ethical dilemmas. In 2015, Chinese scientists sparked global controversy when they first edited human embryo cells in the lab with the goal of modifying genes that would make the child resistant to smallpox, HIV, and cholera. Three years later, in November 2018, researcher He Jiankui informed the world that the first set of CRISPR-engineered female twins had been delivered.

To accomplish his goal, Jiankui deleted a region of a receptor on the surface of white blood cells known as CCR5, introducing a rare, natural genetic variation that makes it more difficult for HIV to infect its favorite target, white blood cells. Because Jiankui forged ethical review documents and misled doctors in the process, he was sentenced to three years in prison and fined $429,000 last December.

Coupled with significant ethical conversations necessary for progress, CRISPR will soon provide us the tools to eliminate diseases, create hardier offspring, produce new environmentally resistant crops, and even wipe out pathogens.

Over the arc of your life, the cells in your body divide until they reach what is known as the Hayflick limit, or the number of times a normal human cell population will divide before cell division stops, which is typically about 50 divisions.

What normally follows next is programmed cell death or destruction by the immune system. A very small fraction of cells, however, become senescent cells and evade this fate to linger indefinitely. These lingering cells secrete a potent mix of molecules that triggers chronic inflammation, damages the surrounding tissue structures, and changes the behavior of nearby cells for the worse. Senescent cells appear to be one of the root causes of aging, causing everything from fibrosis and blood vessel calcification to localized inflammatory conditions such as osteoarthritis to diminished lung function.

Fortunately, both the scientific and entrepreneurial communities have begun to work on senolytic therapies, moving the technology for selectively destroying senescent cells out of the laboratory and into a half-dozen startup companies.

Prominent companies in the field include the following:

Unity Biotechnology is developing senolytic medicines to selectively eliminate senescent cells with an initial focus on delivering localized therapy in osteoarthritis, ophthalmology, and pulmonary disease.

Oisin Biotechnologiesis pioneering a programmable gene therapy that can destroy cells based on their internal biochemistry.

SIWA Therapeuticsis working on an immunotherapy approach to the problem of senescent cells.

In recent years, researchers have identified or designed a handful of senolytic compounds that can curb aging by regulating senescent cells. Two of these drugs that have gained mainstay research traction are rapamycin and metformin.

(1) Rapamycin

Originally extracted from bacteria found on Easter Island, rapamycin acts on the m-TOR (mechanistic target of rapamycin) pathway to selectively block a key protein that facilitates cell division. Currently, rapamycin derivatives are widely used for immunosuppression in organ and bone marrow transplants. Research now suggests that use results in prolonged lifespan and enhanced cognitive and immune function.

PureTech Health subsidiary resTORbio (which went public in 2018) is working on a rapamycin-based drug intended to enhance immunity and reduce infection. Their clinical-stage RTB101 drug works by inhibiting part of the mTOR pathway.

Results of the drugs recent clinical trial include decreased incidence of infection, improved influenza vaccination response, and a 30.6 percent decrease in respiratory tract infection.

Impressive, to say the least.

(2) Metformin

Metformin is a widely-used generic drug for mitigating liver sugar production in Type 2 diabetes patients. Researchers have found that metformin also reduces oxidative stress and inflammation, which otherwise increase as we age. There is strong evidence that metformin can augment cellular regeneration and dramatically mitigate cellular senescence by reducing both oxidative stress and inflammation.

Over 100 studies registered on ClinicalTrials.gov are currently following up on strong evidence of metformins protective effect against cancer.

(3) Nutraceuticals and NAD+

Beyond cellular senescence, certain critical nutrients and proteins tend to decline as a function of age. Nutraceuticals combat aging by supplementing and replenishing these declining nutrient levels.

NAD+ exists in every cell, participating in every process from DNA repair to creating the energy vital for cellular processes. Its been shown that NAD+ levels decline as we age.

The Elysium Health Basis supplement aims to elevate NAD+ levels in the body to extend ones lifespan. Elysiums first clinical study reports that Basis increases NAD+ levels consistently by a sustained 40 percent.

These are just a taste of the tremendous momentum that longevity and aging technology has right now. As artificial intelligence and quantum computing transform how we decode our DNA and how we discover drugs, genetics and pharmaceuticals will become truly personalized.

The next article in this series will demonstrate how artificial intelligence is converging with genetics and pharmaceuticals to transform how we approach longevity, aging, and vitality.

We are edging closer toward a dramatically extended healthspanwhere 100 is the new 60. What will you create, where will you explore, and how will you spend your time if you are able to add an additional 40 healthy years to your life?

(1) A360 Executive Mastermind:If youre an exponentially and abundance-minded entrepreneur who would like coaching directly from me, consider joining my Abundance 360 Mastermind, a highly selective community of 360 CEOs and entrepreneurs who I coach for 3 days every January in Beverly Hills, Ca. Through A360, I provide my members with context and clarity about how converging exponential technologies will transform every industry. Im committed to running A360 for the course of an ongoing 25-year journey as a countdown to the Singularity.

If youd like to learn more and consider joining our 2021 membership,apply here.

(2) Abundance-Digital Online Community: Ive also created a Digital/Online community of bold, abundance-minded entrepreneurs called Abundance-Digital. Abundance-Digital is Singularity Universitys onramp for exponential entrepreneursthose who want to get involved and play at a higher level.Click here to learn more.

(Both A360 and Abundance-Digital are part of Singularity Universityyour participation opens you to a global community.)

This article originally appeared ondiamandis.com. Read theoriginal article here.

Image Credit: Arek Socha from Pixabay

See the article here:
A Renaissance of Genomics and Drugs Is Extending Human ...

A gene called AHL15 (AT-hook motif nuclear-localized protein 15) promotes longevity in annual flowering plants, according to a new study published in the journal Nature Plants.

Left: wild-type Arabidopsis thaliana. Right: Arabidopsis thaliana with overexpressed AHL15. Image credit: Omid Karami.

Plants have growing points on their stems. These are groups of stem cells that can form new stems with leaves or flowers, said Professor Remko Offringa from the Institute of Biology Leiden at Leiden University, the Netherlands, and his colleagues.

In perennial plants, a number of those growing points remain vegetative, so that after flowering the plant can continue to grow in the next season. In annual plants, this does not happen and the plant dies.

We discovered a gene that determines whether growing points of a plant will remain vegetative after flowering.

For the study, Professor Offringa and co-authors used Arabidopsis thaliana, a rapidly growing flowering plant native to Europe, Asia and northern parts of Africa.

We overexpressed the AHL15 gene in Arabidopsis so that it is much more active than normal, they explained.

As with perennial plants, in the modified Arabidopsis plants some growing points remain in the vegetative phase.

The plants continue to grow after flowering and can blossom several times.

When the researchers disabled the AHL15 gene, they noticed that the plants had a shorter lifespan.

The discovery of the gene contributes to fundamental knowledge about plant life history and aging, Professor Offringa said.

The gene may also provide answers to the question of why during evolution certain species have become annuals and others have become perennial.

Many food crops, like rice and wheat, are annuals. Keeping some growing points vegetative in such a crop would allow the plants to continue to grow after harvesting. This may allow for several harvests from the same crop and thus to increase the yield per plant.

Farmers also have to plough less often when they grow plants that bloom more often. As a result, the soil biome will remain intact, which fits well with sustainable production in agriculture.

_____

O. Karami et al. A suppressor of axillary meristem maturation promotes longevity in flowering plants. Nat. Plants, published online April 13, 2020; doi: 10.1038/s41477-020-0637-z

Read the original:
Biologists Identify Longevity Gene in Flowering Plants ...

Maintaining a healthy lifestyle, including a well-rounded diet is crucial to prolonging your lifespan.

You could also boost your lifespan by doing regular exercise. Its the miracle cure weve all been waiting for, according to the NHS.

Making some small diet or lifestyle changes could help to increase your life expectancy and avoid an early death.

Drinking green tea is one of the best ways to lower your risk of a premature death, it's been revealed.

READ MORE: How to live longer - including more of this food in your diet may help

"We know there are no guarantees. But genetics account for just 25 percent of a persons longevity. The rest is up to you," said AARP.

"With this collection of some of the most important longevity findings, youll have the road map you need to get to 80, 90, 100 or beyond.

"If coffees not your thing, green tea also has proven longevity cred, likely because it contains powerful antioxidants known as catechins that may help combat diabetes and heart disease.

"In a large study of more than 40,000 Japanese men and women, drinking five or more cups of green tea a day was associated with a 12 percent decrease in mortality among men and a 23 percent decrease among women."

Meanwhile, you could also lower your risk of early death by regularly eating ginger, it's been revealed.

Ginger has been claimed to reduce inflammation in the colon, which has been linked with bowel cancer.

Dried spices provide the highest concentration of antioxidants, whereas freezing them preserves the antioxidants in fresh spices.

Everyone should liberally add a variety of spices to their meals, nutritionists have urged.

Read more:
How to live longer - the best morning tea to prevent an early death and avoid diabetes - Express

Ongoing research into why some people outlive others often confirms what intuition tells us - the importance of eating a nutritious diet, for example. Occasionally, however, research uncovers surprising links and a new study falls into that category. Research published in the International Journal of Environmental Research and Public Health sheds some light on the impact where you live has on your lifespan.

The research suggests that people who live in highly walkable, mixed-age communities may be more likely to live to their 100th birthday.

They also found socioeconomic status to be correlated, and an additional analysis showed that geographic clusters where the probability of reaching centenarian age is high are located in urban areas and smaller towns with higher socioeconomic status.

"Our study adds to the growing body of evidence that social and environmental factors contribute significantly to longevity, said study author Rajan Bhardwaj, a second-year WSU medical student who took an interest in the topic after serving as a home care aide to his aging grandfather.

Commenting on their findings, Ofer Amram, the study's senior author and an assistant professor who runs WSU's Community Health and Spatial Epidemiology (CHaSE) lab, said: "We know from previous research that you can modify, through behaviour, your susceptibility to different diseases based on your genetics."

READ MORE:How to live longer: The diet shown to reduce risk of early death by 18 percent - key foods

Another way to put it, when you live in an environment that supports healthy ageing, this likely impacts your ability to successfully beat your genetic odds through lifestyle changes.

However, there was a gap in knowledge as to the exact environmental and social factors that make for an environment that best supports living to centenarian age, which this study helped to address.

In collaboration with co-authors Solmaz Amiri and Dedra Buchwald, Bhardwaj and Amram looked at state-provided data about the deaths of nearly 145,000 Washingtonians who died at age 75 or older between 2011 and 2015.

The data included information on each person's age and place of residence at the time of death, as well as their sex, race, education level and marital status.

DON'T MISSHigh blood pressure - the five exercises you can do at home to prevent hypertension[TIPS]Dementia warning - one drink you should avoid if you want to prevent the condition[TIPS]Best supplements for the heart - the 3p a day capsules to lower your risk of heart attacks[TIPS]

Based on where the person lived, the researchers used data from the American Community Survey, Environmental Protection Agency, and other sources to assign a value or score to different environmental variables for their neighbourhood.

The variables they looked at included poverty level, access to transit and primary care, walkability, percentage of working age population, rural-urban status, air pollution, and green space exposure.

Subsequently, they conducted a survival analysis to determine which neighbourhood and demographic factors were tied to a lower probability of dying before centenarian age.

They found that neighbourhood walkability, higher socioeconomic status, and a high percentage of working age population (a measure of age diversity) were positively correlated with reaching centenarian status.

"These findings indicate that mixed-age communities are very beneficial for everyone involved," said Bhardwaj.

She added: "They also support the big push in growing urban centres toward making streets more walkable, which makes exercise more accessible to older adults and makes it easier for them to access medical care and grocery stores."

Amram added that neighbourhoods that offer more age diversity tend to be in urban areas, where older adults are likely to experience less isolation and more community support.

Finally, the researchers wanted to see in which areas of the state people had a higher probability of reaching centenarian age. For each neighbourhood, they calculated the years of potential life lost, or the average number of years deceased individuals would have had to continue living to reach age 100.

Neighbourhoods with lower values for years of potential life lost were considered to have a higher likelihood of reaching centenarian age, and vice versa.

When they mapped the years of potential life lost for all neighbourhoods across the state, they saw clusters with high likelihood of living to centenarian age in higher socioeconomic areas in urban centres and small towns.

While the researchers do not directly reference it in this study, happiness may also be a contributing factor.

Extensive evidence shows happiness brings innumerable benefits to longevity.

It is strongly associated with healthier eating habits and living with less stress, both of which are integral to a long life.

More:
How to live longer: Want to live to see 100? Buy a house in this area says new study - Express

The research report on Genomic Biomarker market, covering the COVID-19 impact, provides a comparative analysis of the historical data with the current market scenario to unveil the growth projections for the industry over the analysis period. As per the study, the market is expected to garner substantial returns and showcase a healthy growth rate throughout the forecast duration.

The market analysis boasts of a competitive market intelligence with respect to the major industry trends, sales volume, market size, growth prospects, and revenue estimates. Moreover, information pertaining to the various industry segmentations covers a large portion of the research. The study further extends through an impartial assessment of the key players in the industry.

Request Sample Copy of this Report @ https://www.cuereport.com/request-sample/11554

A gist of the regional analysis of the Genomic Biomarker market:

Request Sample Copy of this Report @ https://www.cuereport.com/request-sample/11554

Other inferences from the Genomic Biomarker market:

Research Methodology:

The report follows a comprehensive and rigorous research methodology to provide you accurate estimates and forecasts of a particular market. The report provides estimates, forecast, and analysis primarily based on secondary research, primary interviews, in-house database and other free as well as paid sources. Besides, the research methodology we follow is a systematic approach to estimate and project the market sizing keeping in mind all the ongoing and upcoming trends of the market.

Reasons for buying this report:

The key questions answered in this report:

Significant Point Mentioned in theResearch report:

Major highlights of the Table of Contentsof the Genomic Biomarker market Size study:

Request Customization on This Report @ https://www.cuereport.com/request-for-customization/11554

Read more:
Genomic Biomarker Market Report, History and Forecast 2015-2025, Breakdown Data by Manufacturers, Key Regions, Types and Application - CueReport

Zinc Market report is to provide accurate and strategic analysis of the Profile Projectors industry. The report closely examines each segment and its sub-segment futures before looking at the 360-degree view of the market mentioned above. Market forecasts will provide deep insight into industry parameters by accessing growth, consumption, upcoming market trends and various price fluctuations.

Zinc Market competition by top manufacturers as follow: , Korea Zinc Group, Nyrstar, Hindustan, Glencore Xstrata, Nexa Resources, Boliden, Shaanxi Nonferrous Metals, Teck, China Minmetals Corp, Noranda Income Fund, Rotometals, Minera Shouxin Peru, Compania Minera Milpo, Zincore Metals, Deutenberg, HATTLER & Sohn GmbH, U.S. Zinc, Ney Metals?Alloys, Chelyabinsk Electrolytic Zinc Plant, EKMEKCIOGULLARI, Accurate Perforating, AirMetals Inc, Clark Perforating, Fairview Architectural, RotoMetals, Umicore Technical Materials, Aldon Corporation, Eljen Technology, All-Chemie, Rheinzink

Get a Sample PDF copy of the report @ https://reportsinsights.com/sample/77967

This has brought along several changes in This report also covers the impact of COVID-19 on the global market.

Global Zinc Market research reports growth rates and market value based on market dynamics, growth factors. Complete knowledge is based on the latest innovations in the industry, opportunities and trends. In addition to SWOT analysis by key suppliers, the report contains a comprehensive market analysis and major players landscape.The Type Coverage in the Market are: Pure ZincZinc AlloyOthers

Market Segment by Applications, covers:ShipCarBridgeOther

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaRest of Asia PacificCentral & South AmericaMiddle East & Africa

To get this report at a profitable rate.: https://reportsinsights.com/discount/77967

Important Features of the report:

Reasons for buying this report:

Access full Report Description, TOC, Table of Figure, Chart, [emailprotected] https://reportsinsights.com/industry-forecast/Zinc-Market-77967About US:

Reports Insights is the leading research industry that offers contextual and data-centric research services to its customers across the globe. The firm assists its clients to strategize business policies and accomplish sustainable growth in their respective market domain. The industry provides consulting services, syndicated research reports, and customized research reports.

Contact US:

:(US) +1-214-272-0234

:(APAC) +91-7972263819

Email:[emailprotected]

Sales:[emailprotected]

Originally posted here:
Global Impact of Covid-19 on Zinc Market to Witness Promising Growth Opportunities During 20202026 with Top Leading Players Hindustan, Glencore...

The ' Genomic Biomarker market' study now available with Market Study Report, LLC, delivers a concise outlook of the powerful trends driving market growth. This report also includes valuable information pertaining to market share, market size, revenue forecasts, regional landscape and SWOT analysis of the industry. The report further elucidates the competitive backdrop of key players in the market as well as their product portfolio and business strategies.

The Genomic Biomarker market report offers a thorough evaluation of this industry space and comprises of insights pertaining to the market tendencies including current remuneration, revenue predictions, market size and market valuation during the analysis timeframe.

A summary of the performance analysis of the Genomic Biomarker market is stated in the document. The study also provides with information concerning the key industry trends and the estimated growth rate of the market. The report delivers details regarding the growth opportunities and the inhibiting factors for this business vertical.

Request a sample Report of Genomic Biomarker Market at:https://www.marketstudyreport.com/request-a-sample/2493307

This study specially analyses the impact of Covid-19 outbreak on the Genomic Biomarker , covering the supply chain analysis, impact assessment to the Genomic Biomarker market size growth rate in several scenarios, and the measures to be undertaken by Genomic Biomarker companies in response to the COVID-19 epidemic.

Key aspects highlighted in the Genomic Biomarker market report:

As per the regional scope of the Genomic Biomarker market:

Genomic Biomarker Market Segmentation:

An overview of the details provided in the Genomic Biomarker market report:

Ask for Discount on Genomic Biomarker Market Report at:https://www.marketstudyreport.com/check-for-discount/2493307

A summary of the Genomic Biomarker market as perthe product type and application scope:

Product landscape:

Product types:

Oncology, Cardiology, Neurology and Nephrology

Key parameters included in the report:

Application Spectrum:

Application segmentation:

Hospitals and Diagnostic and research laboratories

Specifics offered in report:

Other data cited in the report:

Additional information concerning the competitive terrain of the Genomic Biomarker market:

Vendor base of Genomic Biomarker market:

The major players covered in Genomic Biomarker are:, Bio-Rad, Almac, Thermo Fisher Scientific, Beckman Coulter, Epigenomics, Myriad Genetics, Human Longevity, QIAGEN, Roche, Pfizer, Agilent, ValiRx, Illumina, Empire Genomics, Personalis and Eagle Genomics

Major aspects as per the report:

Research objectives:

Report Answers Following Questions:

For More Details On this Report: https://www.marketstudyreport.com/reports/global-genomic-biomarker-market-2020-by-company-regions-type-and-application-forecast-to-2025

Related Reports:

1. Global Polycystic Ovary Syndrome Market 2020 by Company, Regions, Type and Application, Forecast to 2025Read More: https://www.marketstudyreport.com/reports/global-polycystic-ovary-syndrome-market-2020-by-company-regions-type-and-application-forecast-to-2025

2. Global Prostate Cancer Diagnosis and Treatment Market 2020 by Company, Regions, Type and Application, Forecast to 2025Read More: https://www.marketstudyreport.com/reports/global-prostate-cancer-diagnosis-and-treatment-market-2020-by-company-regions-type-and-application-forecast-to-2025

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

Visit link:
Genomic Biomarker Market Size, Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts to 2025...